Labor Day flew by and then summer faded into fall without a word from TG Therapeutics (TGTX) about the outcome of its most important blood cancer drug clinical trial. Results were way past due.

On Tuesday, we learned the reason for the long delay. TG Therapeutics needed all that extra time to gin up an excuse to paper over what is a significant setback and likely failure of its most advanced pipeline effort.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy